Acute myeloid leukemia associated with t(16:21)(p11;q22) in a pediatric patient.

Background Background">Rare subgroups of pediatric patients with acute myeloid leukemia (AML), such as t(16:21) (p11;q22), require international cooperation to establish a proper stratification system to assign clinical risk. Case report Here, we report a 13-year-old female who was admitted for asthenia, fatigue, and intermittent fever. The hematological data showed thrombocytopenia and anemia, and the bone marrow test showed 82.5% blast cells, which were positive for CD13, CD33, CD38, and CD117. Blast cells showed negative myeloperoxidase staining and positive periodic acid-Schiff staining. A diagnosis of AML M6 was made. Cells were positive for the fusion transcript FUS-ERG t(16;21)(p11;q22). The patient achieved morphological remission. However, molecular remission was not achieved, and she died 11 months after diagnosis. Conclusions It is essential to report this sporadic case of AML to provide clinicians with data for clinical decision-making, such as for risk-group stratification. To the best of our knowledge, this is the first association between this translocation and this morphological subtype.

[1]  Tetsuya Mori,et al.  Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report , 2019, Clinical case reports.

[2]  S. Raimondi,et al.  Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. , 2018, Blood.

[3]  J. Rubnitz Current Management of Childhood Acute Myeloid Leukemia , 2017, Pediatric Drugs.

[4]  B. Jiang,et al.  [Clinical characteristics of acute myeloid leukemia with t (16;21) (p11;q22):nine cases report and literature review]. , 2016, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[5]  G. Leverger,et al.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Zwaan,et al.  Pediatric AML: From Biology to Clinical Management , 2015, Journal of clinical medicine.

[7]  Y. Hayashi,et al.  Childhood acute myeloid leukemia with bone marrow eosinophilia caused by t(16;21)(q24;q22) , 2012, International Journal of Hematology.

[8]  R. Pieters,et al.  Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia , 2011, Haematologica.

[9]  C. Férec,et al.  RUNX1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21)(q24;q22): case report and review of the literature. , 2008, Cancer genetics and cytogenetics.

[10]  T. Nagase,et al.  The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. , 1998, Blood.

[11]  Y. Hayashi,et al.  Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. , 1997, Blood.

[12]  M. Höglund,et al.  Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22) , 1994, Genes, chromosomes & cancer.